Intranasal Azelastine for Recurrent Acute Rhinosinusitis Prophylaxis: A Multicenter Retrospective Study
KEY POINTS: Self-controlled analysis: mean episodes reduced from 2.72 to 1.18 per year; 56.6% reduction. Treatment effect consistent across subgroups, from patients using intranasal corticosteroids (ICS) to those with concurrent chronicc rhinosinusitis (CRS). Findings support prospective randomized controlled trial evaluation of azelastine for recurrent acute rhinosinusitis (RARS).
Authors
- Yixuan James Zheng (ORCID: https://orcid.org/0000-0002-6479-6058)
- Chadi A. Makary (ORCID: https://orcid.org/0000-0001-9967-4045)
- Masayoshi Takashima (ORCID: https://orcid.org/0000-0001-9790-3529)
- Jake Hacker
- Ron L. Moses
- Akshay R. Prabhakar
- Justina Varghese (ORCID: https://orcid.org/0009-0001-8397-4155)
- Samuel E. Razmi
- Utkarsh Singh
- William Marshall
- Omar G. Ahmed
Institutions
- West Virginia University (US)
- Methodist Hospital (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2026-08-14
- DOI
- https://doi.org/10.1002/alr.70244
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00